Edoxaban

Source: Wikipedia, the free encyclopedia.

Edoxaban
Clinical data
Trade namesSavaysa, Lixiana, Roteas, others
Other namesDU-176b
AHFS/Drugs.comMonograph
MedlinePlusa614055
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
CES1, CYP3A4/5, hydrolysis, glucuronidation[6]
Elimination half-life10–14 hours[6]
Excretion62% feces, 35% urine
Identifiers
  • N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide
JSmol)
  • CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C
  • InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1 ☒N
  • Key:HGVDHZBSSITLCT-JLJPHGGASA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Edoxaban, sold under the brand name Lixiana among others, is an

direct factor Xa inhibitor.[3] It is taken by mouth.[3]

Compared with warfarin it has fewer drug interactions.[6]

It was developed by

venous thromboembolisms following lower-limb orthopedic surgery.[7] It was also approved in the United States by the Food and Drug Administration (FDA) in January 2015, for the prevention of stroke and non–central-nervous-system systemic embolism.[8][9] It was approved for use in the European Union in June 2015.[4] It is on the World Health Organization's List of Essential Medicines.[10]

Medical uses

In the United States, edoxaban is

nonvalvular atrial fibrillation.[3][11]

In the European Union, edoxaban is indicated for preventing blood clots in people with nonvalvular atrial fibrillation who also have at least one risk factor, such as having had a previous

congestive heart failure or being 75 years of age or older. It is also used to treat deep vein thrombosis and pulmonary embolism and to prevent either of these from reoccurring.[4]

Contraindications and notes

Edoxaban is often contraindicated in people (incomplete list):

Edoxaban (incomplete list):

Adverse effects

May affect up to 1 in 10 people:[12]

  • stomach ache
  • abnormal results of blood tests that measure liver function
  • anemia
  • bleeding from the skin, nose, vagina, bowel, mouth, throat or stomach
  • rash
  • bloody urine
  • dizziness
  • feeling sick
  • headache
  • itching

May affect up to 1 in 100 people:[12]

  • bleeding in the eyes, brain, after a surgical operation or other types of bleeding
  • blood in the spit when coughing
  • reduced number of platelets in blood
  • allergic reaction
  • hives

May affect up to 1 in 1000 people: bleeding in the muscles, joints, abdomen, heart or inside the skull.[12]

Overdose

Edoxaban overdose can cause serious bleeding.[4] No approved antidotes for edoxaban overdose exist as of April 2021.[4] Hemodialysis does not significantly contribute to edoxaban clearance.[3][12] Andexanet alfa has been studied as an antidote for edoxaban overdose, but has only been approved for reversing rivaroxaban and apixaban effects by the FDA and the EMA as of 2019.[13][14]

Mechanism of action

Edoxaban is a direct,

factor Va on platelet surfaces. Prothrombinases turn prothrombins to thrombins. Thrombins turn blood-soluble fibrinogens to insoluble fibrins, which are the main components of blood clots.[6]

Pharmacokinetics

In human, 15–150 mg oral doses of edoxaban reach their maximum concentrations in blood 1–2 hours after ingestion. With 60 mg doses of isotope labeled edoxaban, 97% of the total radiation was detected after oral administration, with 62% from feces and 35% from urine. 49% of the total radiation from the feces and 24% from the urine were from edoxaban, the rest from its metabolites.[6]

Metabolism occurs mostly via

glucuronosyltransferases.[6]

References

  1. ^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
  2. ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
  3. ^ a b c d e f g "Savaysa- edoxaban tosylate tablet, film coated". DailyMed. 24 April 2020. Retrieved 23 July 2020.
  4. ^ a b c d e "Lixiana EPAR". European Medicines Agency (EMA). Retrieved 23 July 2020.
  5. ^ "Roteas EPAR". European Medicines Agency (EMA). Retrieved 25 September 2020.
  6. ^
    PMID 26620048
    .
  7. ^ "First market approval in Japan for Lixiana (Edoxaban)". Daiichi Sankyo Europe GmbH (Press release). 22 April 2011. Archived from the original on 6 November 2013.
  8. ^ O'Riordan M (9 January 2015). "FDA Approves Edoxaban for Stroke Prevention in AF and DVT/PE Prevention". Medscape. Retrieved 10 January 2015.
  9. ^ "Drug Approval Package: Savaysa (edoxaban tosylate) Tablets NDA #206316". U.S. Food and Drug Administration (FDA). 13 February 2015. Retrieved 23 July 2020.
  10. hdl:10665/345533
    . WHO/MHP/HPS/EML/2021.02.
  11. PMID 30383133
    .
  12. ^ a b c d e f g h i j k "Lixiana, INN-edoxaban" (PDF). Archived (PDF) from the original on 6 November 2019. Retrieved 6 November 2019.
  13. ^ Ovanesov M (3 August 2017). "Summary basis for regulatory action - ANDEXXA". Food and Drug Administration. Retrieved 6 November 2019.
  14. ^ "Ondexxya". European Medicines Agency. 27 February 2019. Archived from the original on 16 July 2019. Retrieved 6 November 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Edoxaban&oldid=1217670478"